COVID-19 and arthritis

The global pandemic of coronavirus disease 2019 (COVID-19) has resulted in severe morbidity and mortality. During the pandemic, patients with arthritis confront specific obstacles, including infection risk, medicine shortages, restricted access to care, social isolation, and mental health issues. The impact of the COVID-19 pandemic on people with arthritis will be examined in this review. Older age and comorbidities are risk factors for catastrophic COVID-19 outcomes in arthritis patients, just as they are in the general population. Glucocorticoids appear to be linked to a greater risk of severe COVID-19 outcomes, but not other kinds of disease-modifying anti rheumatic medications (DMARDs). Changes in access to care, telemedicine, prescription shortages, anxiety, and social isolation have all impacted arthritis sufferers, perhaps contributing to disease flares.

 

    Related Conference of COVID-19 and arthritis

    February 24-25, 2025

    34th European Diabetes Congress

    London, UK
    March 10-11, 2025

    4th Global Summit on Physiology and Metabolism of Thyroid

    Singapore City, Singapore
    March 17-18, 2025

    5th European Endocrinology and Diabetes Congress

    Paris, France
    April 10-11, 2025

    5th World Congress on Endocrine and Diabetes

    Dubai, UAE
    April 10-11, 2025

    4th International Summit on Hormonal Disorders

    Dubai, UAE
    May 19-20, 2025

    6th World Summit on Diabetes

    Rome, Italy
    June 04-05, 2025

    4th World Congress on Diabetes and Pediatric Endocrinology

    Edinburgh, Scotland
    July 29-30, 2025

    15th World Congress on Endocrinology and Diabetes

    Aix-en-Provence, France
    September 08-09, 2025

    3rd World congress and Expo on Diabetes

    Frankfurt, Germany
    November 20-21, 2025

    21st World Congress on Endocrinology & Diabetes

    Aix-en-Provence, France

    COVID-19 and arthritis Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in